Payment overview · 2025
General Payments
$151.01
3 reported records · 2 companies
Healthcare provider profile · identity verified
Rita Carabello, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1952346983
Verified facts
What the public records show
CMS Open Payments records show Rita Carabello, D.O. received $151.01 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 89.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $134.69 | 89.2% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.32 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.01 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $122.22 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $12.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 128 |
| Losartan Potassium | Losartan Potassium | 340 | 96 |
| Metformin Hcl | Metformin Hcl | 303 | 92 |
| Gabapentin | Gabapentin | 263 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 73 |
| Lisinopril | Lisinopril | 248 | 76 |
| Omeprazole | Omeprazole | 246 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 190 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 44 |
| Alprazolam | Alprazolam | 157 | 24 |
| Jardiance | Empagliflozin | 149 | 39 |
| Montelukast Sodium | Montelukast Sodium | 144 | 38 |
| Ezetimibe | Ezetimibe | 143 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 33 |
| Trazodone Hcl | Trazodone Hcl | 130 | 30 |
| Carvedilol | Carvedilol | 128 | 30 |
| Simvastatin | Simvastatin | 97 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 19 |
| Alendronate Sodium | Alendronate Sodium | 78 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 23 |
| Furosemide | Furosemide | 77 | 29 |
| Famotidine | Famotidine | 76 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | suppressed |
| Ozempic | Semaglutide | 74 | 16 |
| Pregabalin | Pregabalin | 74 | 11 |
| Atenolol | Atenolol | 72 | 18 |
| Ibuprofen | Ibuprofen | 67 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 22 |
| Baclofen | Baclofen | 64 | 11 |
| Glimepiride | Glimepiride | 64 | 17 |
| Farxiga | Dapagliflozin Propanediol | 62 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Valsartan | Valsartan | 55 | 14 |
| Januvia | Sitagliptin Phosphate | 52 | 12 |
| Allopurinol | Allopurinol | 51 | 11 |
| Eliquis | Apixaban | 51 | 17 |
| Trulicity | Dulaglutide | 51 | 11 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Diazepam | Diazepam | 50 | suppressed |
| Glipizide | Glipizide | 47 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 15 |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 44 | 15 |
| Nifedipine Er | Nifedipine | 43 | 13 |
| Methylprednisolone | Methylprednisolone | 41 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 14 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Lovastatin | Lovastatin | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 12 |
| Sertraline Hcl | Sertraline Hcl | 36 | 13 |
| Meloxicam | Meloxicam | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 25 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Lidocaine | Lidocaine | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Fluconazole | Fluconazole | 17 | 11 |
| Prednisone | Prednisone | 17 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.01 · 3 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error